ACR-Pedi, cJADAS-10 and ACR provisional clinical inactive disease responses with etanercept in the effectiveness cohort by complete case analysis
| Outcome | Response | |
| At 6-month follow-up N=32 | At 12-month follow-up N=22 | |
| ACR-Pedi Response, n (%) (number of patients with complete data) | ||
| ACR30 | 12 (80.0) (15) | 4 (80.0) (5) |
| ACR50 | 10 (66.7) (15) | 4 (80.0) (5) |
| ACR70 | 10 (66.7) (15) | 3 (60.0) (5) |
| ACR90 | 7 (46.7) (15) | 1 (20.0) (5) |
| cJADAS-10 | ||
| Median (Q1, Q3) (number of patients with complete data) | 2.5 (0.5, 6.0) (25)21 | 0 (0, 3.0) (13) |
| ≤ 1.1, n (%) (number of patients with complete data)* | 9 (36.0) (25) | 7 (53.8) (13) |
| ≤ 2.5, n (%) (number of patients with complete data)* | 13 (52) (25) | 9 (69.2)12 (13) |
| Change in cJADAS-10, median (Q1, Q3) (number of patients with complete data) | –2.8 (–6.0, –1.0) (18) | –5.5 (–7.0, –2.8) (8) |
| Active enthesitis present, n (%) (number of patients with complete data) | 5 (20.9) (39) | 3 (10.0) (30) |
| ACR provisional clinical inactive disease, n (%) (number of patients with complete data) | 14 (51.9) (27) | 7 (43.8) (16) |
N=number of patients who initiated etanercept after CARRA Registry enrolment, had a registry visit ±14 days from etanercept initiation, had uninterrupted etanercept use and had a 6-month or 12-month follow-up visit; n=number of patients with outcome. Responses could not be calculated for patients with missing observations at the baseline or a follow-up visit.
*Since the cJADAS-10 has not been validated for JPsA, we included cut-off values for inactive disease for oligoarthritis and polyarthritis.
ACR, American College of Rheumatology; ACR-Pedi Response, American College of Rheumatology-Pediatric Response; CARRA, Childhood Arthritis and Rheumatology Research Alliance; cJADAS-10, clinical Juvenile Arthritis Disease Activity Score 10-joint; JPsA, juvenile psoriatic arthritis; Q1, quartile 1; Q3, quartile 3.